作者: Robert P Nelson Jr , Muhammad Rizwan Khawaja , Susan M Perkins , Lindsey Elmore , Christen L Mumaw
DOI: 10.1016/J.BBMT.2014.06.039
关键词:
摘要: Abstract Five candidate plasma biomarkers (suppression of tumorogenesis 2 [ST2], regenerating islet-derived-3α [REG3α], elafin, tumor necrosis factor receptor 1 [TNFR1], and soluble IL-2 receptor-alpha [sIL2Rα]) were measured at specific time points after cyclophosphamide/fludarabine-based nonmyeloablative allotransplantation (NMAT) in patients who did or not develop acute graft-versus-host disease (aGVHD). Plasma samples from 34 analyzed days +7, +14, +21, and +30. At a median follow-up 358 days, 17 had experienced aGVHD with to onset day +36. Risk was associated elevated ST2 concentrations day +7 (c-statistic = .72, P = .03), day +14 (c-statistic = .74, P = .02), day +21 (c-statistic = .75, P = .02); REG3α (c-statistic = .73, (c-statistic = .76, P = .01), day +30 P = .03); elafin (c-statistic = .71, P = .04). TNFR1 sIL2Rα associated risk any the studied. This study identified ST2, REG3α, as prognostic evaluate NMAT. These results need be confirmed an independent validation cohort.